

BMB Reports – Manuscript Submission

Manuscript Draft

Manuscript Number: BMB-22-017

Title: AURKB, in concert with REST, acts as an oxygen-sensitive epigenetic regulator of the hypoxic induction of MDM2

Article Type: Article

Keywords: hypoxia; histone phosphorylation; AURKB; REST; MDM2

Corresponding Author: Jong-Wan Park

Authors: Iljin Kim^{1, #}, Sanga Choi^{1, #}, Seongkyeong Yoo¹, Mingyu Lee², Jong-Wan Park^{3, 4, *}

Institution: ¹Pharmacology, Inha University College of Medicine,

²Medicine, Brigham and Women's Hospital, Harvard Medical School,

³Pharmacology, Seoul National University College of Medicine,

⁴Cancer Research Institute and Ischemic/Hypoxic Disease Institute, Seoul National University College of Medicine,

AURKB, in concert with REST, acts as an oxygen-sensitive epigenetic regulator of the hypoxic induction of MDM2

Iljin Kim^{1,#}, Sanga Choi^{1,#}, Seongkyeong Yoo¹, Mingyu Lee², Jong-Wan Park^{3,4,*}

¹Department of Pharmacology, Inha University College of Medicine, Incheon, Korea.

²Division of Allergy and Clinical Immunology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.

³Department of Pharmacology, Seoul National University College of Medicine, Seoul, Korea.

⁴Cancer Research Institute and Ischemic/Hypoxic Disease Institute, Seoul National University College of Medicine, Seoul, Korea.

[#]These authors contributed equally to this work.

***Corresponding author:** Jong-Wan Park, M.D., Ph.D., Department of Pharmacology, Seoul National University College of Medicine, 103 Daehak-ro, Seoul 03080, South Korea. Phone: +82-2-740-8289; Fax: +82-2-745-7996; Email: parkjw@snu.ac.kr

Running title: Oxygen-sensitive epigenetic regulation by AURKB

Abstract

The acute response to hypoxia is mainly driven by hypoxia-inducible factors, but their effects gradually subside with time. Hypoxia-specific histone modifications may be important for the stable maintenance of long-term adaptation to hypoxia. However, little is known about the molecular mechanisms underlying the dynamic alterations of histones under hypoxic conditions. We found that the phosphorylation of histone H3 at Ser-10 (H3S10) was noticeably attenuated after hypoxic challenge, which was mediated by the inhibition of aurora kinase B (AURKB). To understand the role of AURKB in epigenetic regulation, DNA microarray and transcription factor binding site analyses combined with proteomics analysis were performed. **Under normoxia, phosphorylated AURKB, in concert with the repressor element-1 silencing transcription factor (REST), phosphorylates H3S10, which allows the AURKB–REST complex to access the *MDM2* proto-oncogene.** REST then acts as a transcriptional repressor of *MDM2* and downregulates its expression. Under hypoxia, AURKB is dephosphorylated and the AURKB–REST complex fails to access *MDM2*, leading to the upregulation of its expression. In this study, we present a case of hypoxia-specific epigenetic regulation of the oxygen-sensitive AURKB signaling pathway. To better understand the cellular adaptation to hypoxia, it is worthwhile to further investigate the epigenetic regulation of genes under hypoxic conditions.

Keywords: hypoxia; histone phosphorylation; AURKB; REST; MDM2

INTRODUCTION

Acute responses to hypoxia are delicately regulated at the transcriptional level by oxygen-sensitive hydroxylases, such as the egl-9 family hypoxia inducible factor (EGLN/PHD)1–3, factor inhibiting HIF (FIH), and the hypoxia-inducible factor (HIF)-1/2 (1). The cellular levels of HIF-1/2 increase immediately after hypoxic challenge but gradually subside with time, even under hypoxia (2, 3). Therefore, gene regulation at the epigenetic level is suggested to lead to long-term adaptation to hypoxia. So far, oxygen-sensitive epigenetic regulation has not been extensively studied. In recent years, the methylation of histone H3 at several lysine residues has been induced during hypoxia, leading to the activation or repression of specific gene sets (4, 5). However, histone modifications, except methylation, in response to hypoxia remain largely unexplored.

Histone phosphorylation is involved in diverse cellular functions, such as gene expression, mitosis, and DNA damage response (6). Histone phosphorylation is reciprocally regulated by protein kinases and phosphatases. Kinases catalyze the transfer of a phosphoryl group and confer a negative charge to histones, which weakens the electrostatic interaction between histones and DNA and subsequently provides an open space for transcription factors (7). Aurora kinase B (AURKB) is a protein kinase that phosphorylates the histone H3 at Ser-10 (H3S10). The AURK family includes three serine/threonine kinases: AURK-A, B, and C. They commonly contain a highly conserved kinase domain in the middle. The kinase domain of AURKB contains a conserved phosphorylation site at Thr-232, and autophosphorylation at this residue induces a conformational change that determines its kinase activity towards its substrates, including histone H3 (8).

Repressor element-1 silencing transcription factor (REST), also called the neuron-restrictive silencer factor, is a transcriptional repressor that binds to specific gene regions (9). REST binds to repressor element-1 within its target gene promoters, and can also target distant or non-consensus gene loci (10). On chromatin, REST sequentially recruits several key corepressors, chromatin modifiers, and the chromatin remodeling machinery (11). Although REST was initially considered as a master regulator of neurogenesis, it has also been implicated in the regulation of various non-neuronal biological processes (12-14).

In this study, for the first time, we reported the oxygen-dependent phosphorylation of histone H3S10. We also found that AURKB is activated in an oxygen-dependent manner and phosphorylated H3S10 under normoxic conditions. Furthermore, AURKB interacts with and recruits REST to the *MDM2* promoter, thereby downregulating *MDM2* expression. Under hypoxia, this process is inhibited and *MDM2* expression is upregulated. These results imply that the oxygen-sensitive epigenetic regulation contributes to cellular adaptation to hypoxia independent of the HIF signaling pathway.

RESULTS

Hypoxia inhibits AURKB-dependent histone H3S10 phosphorylation in an HIF-independent manner

In the search for hypoxia-regulated histone modifications, we found that the phosphorylation of histone H3S10 was reduced under hypoxia. First, we incubated various human cells under hypoxic conditions to analyze their phosphorylation status. Because AURKB is known to be the major kinase of H3S10, we checked the cellular levels of AURKB and analyzed its active phospho-Thr-232 form. Cells were harvested and subjected to histone extraction followed by immunoblotting analysis. The total protein levels of H3 and AURKB did not change, but the phosphorylated levels of both proteins were substantially reduced under hypoxic conditions (Fig. 1A). As H3S10 phosphorylation was reduced by AURKB inhibition or knockdown (Supplementary Fig. S1A and B), AURKB was confirmed to be a kinase for H3S10. Both H3S10 and AURKB phosphorylation were reduced in a hypoxic time-dependent manner (Fig. 1B), but were almost completely restored after 8 h of incubation under normoxia (Fig. 1C).

HIFs, including HIF-1 and HIF-2, are master regulators of oxygen homeostasis (1). To examine whether hypoxic inhibition of H3S10 and AURKB phosphorylation is driven by HIF signaling, we overexpressed a stable and constitutively active form of HIF-1 α (scHIF-1 α). However, the phosphorylated forms of both proteins were unaffected by HIF-1 α overexpression (Fig. 1D). Moreover, hypoxic inhibition of H3S10 and AURKB phosphorylation was not affected by the HIF-1/2 α knockdown (Fig. 1E). To further evaluate HIF-independent events, we tested various drugs known to stabilize HIF (15-17). Although HIF-1 α was profoundly induced by dimethyloxallyl glycine, JNJ-42041935, or VH298, the phosphorylation of H3S10 and AURKB was not reduced (Fig. 1F). As expected, AZD1152, a selective AURKB inhibitor, markedly

decreased H3S10 and AURKB phosphorylation, but failed to stabilize HIF-1 α . Next, we examined the involvement of the oxygen sensors, PHD1-3 and FIH, in phosphorylation. Oxygen sensors mediate oxygen-dependent regulation of HIFs for protein stability and transcriptional activity (1). Consistently, knockdown of each oxygen sensor did not affect H3S10 and AURKB phosphorylation (Fig. 1G). Collectively, these results suggest that hypoxia blocks H3S10 and AURKB phosphorylation, regardless of previously known oxygen-sensing pathways.

Identification of transcription factors targeting the hypoxia response genes in concert with AURKB

Based on the hypothesis that AURKB-mediated H3 phosphorylation epigenetically regulates hypoxia response genes, we sought to identify the genes regulated in an AURKB-dependent manner. Four experimental groups according to AURKB expression and culture conditions were established (Fig. 2A). In the RNA samples subjected to DNA microarray analyses, the expression levels of AURKB and vascular endothelial growth factor A (a representative index for cellular response to hypoxia) were determined using reverse transcription-quantitative polymerase chain reaction (RT-qPCR). RT-qPCR verified that RNA samples were extracted from cells that responded properly to the four distinct conditions (Fig. 2B). **Consequently, DNA microarray analyses identified 61 genes that were differentially expressed in response to hypoxia and AURKB knockdown by small interfering RNA (Fig. 2C).** In this study, we hypothesized that AURKB suppression determines the expression of certain genes under hypoxic conditions. If so, the target genes might be regulated either by hypoxia or AURKB suppression under normoxia. In the heatmap clustering analysis, the expression levels of 41 genes were found to be upregulated by hypoxia and AURKB

suppression, while those of 20 genes were downregulated under the same conditions (Fig. 2D). Potential target genes are listed in Supplementary Tables S1 and 2. Next, we used the TRANScriptioN FACtor (TRANSFAC) database upstream analysis program to identify potential transcription factors that could regulate these genes. Transcription factors were ranked on the basis of their fold-change values derived by comparing the number of transcription factor-binding sites between our gene sets and the reference gene sets (Fig. 2E). Notably, the number of binding sites does not indicate the probability of DNA binding. Next, we performed proteomic screening analysis to determine which candidate proteins interacted with AURKB. Mass spectrometric analyses, which were performed at least twice in three independent experiments, revealed 576 proteins that potentially interacted with AURKB. Of the interactomes, REST and tripartite motif-containing 28 (TRIM28) were commonly detected in the TRANSFAC and proteomic analyses (Fig. 2F).

AURKB interacts with REST

Results of the immunoprecipitation assay showed that AURKB interacted with REST at endogenous levels, but not substantially with TRIM28 (Fig. 3A). AURKB–REST binding was double-checked by swapping the antibodies used for immunoprecipitation and western blotting (Fig. 3B). To examine whether T232 autophosphorylation of AURKB is essential for this interaction, we expressed a mutated AURKB (T232A) in which T232 was substituted with Ala. There was no difference in the apparent binding affinity for REST between the wild-type and mutant; therefore, autophosphorylation of AURKB was determined to be non-essential for this interaction (Fig. 3C). Furthermore, the AURKB-REST interaction was unaffected by hypoxia (Fig. 3D). These results

indicate that the interaction between AURKB and REST occurs regardless of AURKB phosphorylation or ambient oxygen tension.

AURKB is essential for REST recruitment to *MDM2*

Histone phosphorylation relaxes chromatin structure, allowing transcription factors to access the target genes. Given the role of histone phosphorylation, we examined whether phosphorylation of H3S10 facilitated REST to access the target genes. Of the 61 potential target genes shown in Fig. 2D, 25 with high potential REST-binding scores were screened using the chromatin immunoprecipitation (ChIP)-Atlas database (Fig. 4A). To identify the actual target genes of REST, we listed the top 10 genes with high REST-binding scores (Fig. 4B). By overexpressing or knocking down REST, we confirmed that REST robustly controlled the expression of *MDM2* (Fig. 4C and D). Under hypoxic conditions, *MDM2* mRNA levels were upregulated in the control cells. This suggests that *MDM2* is repressed under normoxia but upregulated under hypoxia. More importantly, REST overexpression augmented *MDM2* repression under normoxia, but not under hypoxia (Fig. 4E). This indicates that REST acts as an *MDM2* repressor in an oxygen-dependent manner. Similarly, AURKB knockdown enhanced *MDM2* mRNA expression levels in control cells. This suggests that AURKB participates in *MDM2* repression under normoxic conditions. In addition, REST overexpression augmented *MDM2* repression in control cells, but not in AURKB knockdown cells (Fig. 4F). This regulation of *MDM2* expression was further confirmed at the protein level (Supplementary Fig. S2A and B). This finding supports our hypothesis that AURKB is essential for REST-driven *MDM2* repression under normoxic conditions. In addition, ChIP analysis showed that REST recruitment to the *MDM2* promoter was significantly reduced under hypoxia (Fig. 4G) and AURKB knockdown under normoxia (Fig. 4H).

MDM2 is best known for its role in inhibiting the stability and transcriptional activity of the tumor suppressor p53 (18). To further verify its downstream functions, we performed a qPCR screening assay against known transcriptional targets of p53 (19) upon AURKB overexpression. Indeed, in p53 wild-type A549 cells, several p53 target genes (eight out of 91) were found to be activated by AURKB, but this change was not observed in p53 null H1299 cells (Supplementary Fig. S3). Taken together, these results further support our hypothesis that AURKB allows REST to access *MDM2* via phosphorylation of H3S10.

DISCUSSION

Epigenetic regulation of hypoxia-responsive genes is an emerging topic in the field of hypoxic biology. Previous studies have documented several histone methyltransferases and demethylases as oxygen-sensitive regulators of gene expression (20). For instance, histone demethylases, lysine demethylase (KDM)-6A and KDM5A, directly sense oxygen and modify the chromatin structure of a subset of hypoxia response genes (5, 21). The histone methyltransferases, G9a and GLP, are also regulated by the oxygen sensor FIH, which determines the oxygen-dependent methylation of H3K9 (4). In contrast, histone phosphorylation in response to hypoxia is relatively unknown. Here, we show that hypoxia inhibits AURKB to control H3S10 phosphorylation for proper gene expression. H3S10 phosphorylation is a marker of mitotic progression that is required for proper chromosome condensation and segregation during cell division. In interphase, H3S10 phosphorylation regulates the transcription of specific genes (22). We previously showed that AURKB regulates the activity of the cyclin D1 promoter via H3S10 phosphorylation (23).

In hypoxia signaling, AURKB promotes ChIP-dependent degradation of HIF-1 α by phosphorylating HIF-1 α at multiple serine residues (24). However, little is known about the oxygen-dependent changes in AURKB and H3S10 phosphorylation. H3S10 phosphorylation is generally considered an active marker that promotes the recruitment of transcriptional activators to target genes (22). However, the outcome of H3S10 phosphorylation may vary depending on the target gene. Here, we demonstrated that H3S10 phosphorylation downregulated *MDM2* expression by forming a chromatin structure that favored the recruitment of REST to *MDM2*. Despite many efforts, however, we failed to uncover the mechanism underlying the oxygen-dependent activation of AURKB. It was confirmed that AURKB and H3S10 phosphorylation were

not regulated via the HIF-related oxygen-sensing pathway. Therefore, it is plausible that AURKB is regulated by a novel oxygen-sensing system. It is possible that the upstream factor of AURKB is directly regulated by oxygen or oxygen-containing molecules. Alternatively, changes in the cellular context due to hypoxia could indirectly inhibit AURKB autophosphorylation. However, this requires further investigation in future studies.

The E3 ubiquitin ligase, MDM2, ubiquitinates its specific substrates for degradation via the proteasomal system, and its expression is modulated by a variety of stress signals (25). To accomplish this wide range of pleiotropic activities, MDM2 interacts with 100 or more proteins (26). In response to hypoxia, MDM2 regulates two important transcription factors, p53 and HIF-1 α . Hypoxia can affect MDM2 at both the mRNA and protein levels, and its expression can be increased or decreased depending on the cellular context (27). MDM2 is overexpressed in several human malignancies due to gene amplification or other yet-to-be-discovered processes. Its oncogenic activity is attributed to the inhibition of the tumor suppressor p53 (18). MDM2 physically blocks the transcriptional activation domain of p53 and simultaneously degrades it via ubiquitination. Therefore, drugs that block the MDM2–p53 interaction have been developed as anticancer agents to induce cell cycle arrest and apoptosis (28). In contrast, MDM2 interacts with and activates HIF-1, which enhances tumor adaptation to hypoxia (29). MDM2 inhibits HIF-1 signaling by promoting the ubiquitination and degradation of HIF-1 α (30, 31). In this study, we demonstrated that hypoxia upregulates *MDM2* expression by inhibiting REST-driven gene repression. When the cells are under hypoxia, this epigenetic upregulation of MDM2 may play a role in cell survival by either inhibiting p53-mediated apoptosis or fine-tuning HIF

signaling. These findings provide a better understanding of the mechanism by which the cells cope under hypoxic conditions.

In conclusion, our results reveal a novel mechanism of gene regulation that occurs via the hypoxic suppression of histone phosphorylation. AURKB phosphorylates H3S10 under normoxia and guides its binding partner, REST, to the *MDM2* promoter. Under hypoxia, however, AURKB fails to phosphorylate H3S10 due to an uncertain process; hence, REST cannot access the promoter (Fig. 4I).

MATERIALS AND METHODS

Further information is described in Supplementary Materials and Methods.

Plasmids and siRNAs

AURKB cDNA was cloned by RT-PCR and inserted into pcDNA vector (Promega, Madison, WI). REST cDNA clone was obtained from OriGene Technologies (Rockville, MD). HA-sHIF-1 α was constructed as previously described (32). Site-directed mutagenesis kit was used to create the mutant constructs (Stratagene, La Jolla, CA). All siRNAs were purchased from Integrated DNA Technologies (Coralville, IA) and listed in Supplementary Table S3.

ChIP, RT-qPCR, and DNA microarray

ChIP assay (Merck, Darmstadt, Germany) and RT-qPCR (Enzynomics, Daejeon, South Korea) kits were used as per the manufacturer's instructions. Supplementary Table S4 contains the primer sequences for PCR. DNA microarray was performed commercially by Ebiogen (Seoul, South Korea).

Immunoprecipitation, Western blot, and mass spectrometric analyses

Immunoprecipitation and Western blot were performed as previously described with minor modifications (33). Anti-HIF-1 α antibody used in Western blot was generated as previously described (34). Mass analysis was performed on a Q-Exactive Orbitrap mass spectrometer (Thermo Fisher Scientific, Waltham, MA).

ACKNOWLEDGMENTS

This study was supported by the National Research Foundation of Korea (2019R1A2B5B03069677, 2020R1A4A2002903, and 2021R1C1C2004561).

CONFLICT OF INTEREST

The authors declare no conflict of interest.

AUTHOR CONTRIBUTIONS

J.W.P. supervised the study. I.K. designed and performed the experiments with assistance from S.C., S.Y., M.L., and I.K. analyzed proteomics data. I.K. and J.W.P. wrote the manuscript. All authors commented on the manuscript.

REFERENCES

1. Kaelin WG, Jr. and Ratcliffe PJ (2008) Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. *Mol Cell* 30, 393-402
2. Bartoszewski R, Moszynska A, Serocki M et al (2019) Primary endothelial cell-specific regulation of hypoxia-inducible factor (HIF)-1 and HIF-2 and their target gene expression profiles during hypoxia. *Faseb Journal* 33, 7929-7941
3. Ginouves A, Ilc K, Macias N, Pouyssegur J and Berra E (2008) PHDs overactivation during chronic hypoxia "desensitizes" HIF alpha and protects cells from necrosis. *Proceedings of the National Academy of Sciences of the United States of America* 105, 4745-4750
4. Kang J, Shin SH, Yoon H et al (2018) FIH Is an Oxygen Sensor in Ovarian Cancer for G9a/GLP-Driven Epigenetic Regulation of Metastasis-Related Genes. *Cancer Res* 78, 1184-1199
5. Chakraborty AA, Laukka T, Myllykoski M et al (2019) Histone demethylase KDM6A directly senses oxygen to control chromatin and cell fate. *Science* 363, 1217-+
6. Perez-Cadahia B, Drohic B and Davie JR (2009) H3 phosphorylation: dual role in mitosis and interphase. *Biochem Cell Biol* 87, 695-709
7. Baek SH (2011) When Signaling Kinases Meet Histones and Histone Modifiers in the Nucleus. *Molecular Cell* 42, 274-284
8. Willems E, Dedobbeleer M, Digregorio M, Lombard A, Lumapat PN and Rogister B (2018) The functional diversity of Aurora kinases: a comprehensive review. *Cell Division* 13
9. Ooi L and Wood IC (2007) Chromatin crosstalk in development and disease: lessons from REST. *Nature Reviews Genetics* 8, 544-554
10. Cavadas MAS, Mesnieres M, Crifo B et al (2016) REST is a hypoxia-responsive transcriptional repressor. *Scientific Reports* 6
11. Hwang JY and Zukin RS (2018) REST, a master transcriptional regulator in neurodegenerative disease. *Current Opinion in Neurobiology* 48, 193-200
12. Cheong A, Bingham AJ, Li J et al (2005) Downregulated REST transcription factor is a switch enabling critical potassium channel expression and cell proliferation. *Molecular Cell* 20, 45-52
13. Kuwahara K, Saito Y, Ogawa E et al (2001) The neuron-restrictive silencer element-neuron-restrictive silencer factor system regulates basal and endothelin 1-inducible atrial natriuretic peptide gene expression in ventricular myocytes. *Molecular and Cellular Biology* 21, 2085-2097
14. Negrini S, Prada I, D'Alessandro R and Meldolesi J (2013) REST: an oncogene or a tumor suppressor? *Trends Cell Biol* 23, 289-295
15. Barrett TD, Palomino HL, Brondstetter TI et al (2011) Pharmacological Characterization of 1-(5-Chloro-6-(trifluoromethoxy)-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic Acid (JNJ-42041935), a Potent and Selective Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor. *Molecular Pharmacology* 79, 910-920
16. Chan MC, Illott NE, Schodel J et al (2016) Tuning the Transcriptional Response to Hypoxia by Inhibiting Hypoxia-inducible Factor (HIF) Prolyl and Asparaginyl Hydroxylases. *Journal of Biological Chemistry* 291, 20661-20673

17. Frost J, Galdeano C, Soares P et al (2016) Potent and selective chemical probe of hypoxic signalling downstream of HIF- α hydroxylation via VHL inhibition. *Nature Communications* 7
18. Manfredi JJ (2010) The Mdm2-p53 relationship evolves: Mdm2 swings both ways as an oncogene and a tumor suppressor. *Genes Dev* 24, 1580-1589
19. Fischer M (2017) Census and evaluation of p53 target genes. *Oncogene* 36, 3943-3956
20. Kim I and Park JW (2020) Hypoxia-driven epigenetic regulation in cancer progression: A focus on histone methylation and its modifying enzymes. *Cancer Lett* 489, 41-49
21. Batie M, Frost J, Frost M, Wilson JW, Schofield P and Rocha S (2019) Hypoxia induces rapid changes to histone methylation and reprograms chromatin. *Science* 363, 1222-+
22. Komar D and Juszczynski P (2020) Rebelled epigenome: histone H3S10 phosphorylation and H3S10 kinases in cancer biology and therapy. *Clin Epigenetics* 12, 147
23. Nie M, Wang YD, Yu ZN et al (2020) AURKB promotes gastric cancer progression via activation of CCND1 expression. *Aging-Us* 12, 1304-1321
24. Biswas K, Sarkar S, Said N, Brautigan DL and Lerner JM (2020) Aurora B Kinase Promotes CHIP-Dependent Degradation of HIF1 α in Prostate Cancer Cells. *Molecular Cancer Therapeutics* 19, 1008-1017
25. Klein AM, de Queiroz RM, Venkatesh D and Prives C (2021) The roles and regulation of MDM2 and MDMX: it is not just about p53. *Genes Dev* 35, 575-601
26. Fahraeus R and Olivares-Illana V (2014) MDM2's social network. *Oncogene* 33, 4365-4376
27. Zhang L and Hill RP (2004) Hypoxia enhances metastatic efficiency by up-regulating Mdm2 in KHT cells and increasing resistance to apoptosis. *Cancer Res* 64, 4180-4189
28. Shaikh MF, Morano WF, Lee J et al (2016) Emerging Role of MDM2 as Target for Anti-Cancer Therapy: A Review. *Annals of Clinical and Laboratory Science* 46, 627-634
29. Nieminen AL, Qanungo S, Schneider EA, Jiang BH and Agani FH (2005) Mdm2 and HIF-1 α interaction in tumor cells during hypoxia. *J Cell Physiol* 204, 364-369
30. Joshi S, Singh AR and Durden DL (2014) MDM2 regulates hypoxic hypoxia-inducible factor 1 α stability in an E3 ligase, proteasome, and PTEN-phosphatidylinositol 3-kinase-AKT-dependent manner. *J Biol Chem* 289, 22785-22797
31. Ravi R, Mookerjee B, Bhujwalla ZM et al (2000) Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1 α . *Genes Dev* 14, 34-44
32. Kim HL, Yeo EJ, Chun YS and Park JW (2006) A domain responsible for HIF-1 α degradation by YC-1, a novel anticancer agent. *Int J Oncol* 29, 255-260
33. Kim I, Shin SH, Lee JE and Park JW (2019) Oxygen sensor FIH inhibits HACE1-dependent ubiquitination of Rac1 to enhance metastatic potential in breast cancer cells. *Oncogene* 38, 3651-3666

34. Chun YS, Choi E, Kim GT et al (2000) Zinc induces the accumulation of hypoxia-inducible factor (HIF)-1 alpha, but inhibits the nuclear translocation of HIF-1 beta, causing HIF-1 inactivation. *Biochemical and Biophysical Research Communications* 268, 652-656

FIGURE LEGENDS

Fig. 1. Hypoxia inhibits AURKB and H3S10 phosphorylation in a HIF-independent manner. (A) Various cell lines were exposed to hypoxia (1% O₂) for 24 h and subjected to histone extraction. Cell lysates and histone extraction samples were analyzed by Western blotting with the indicated antibodies. (B) A549 cells were incubated in hypoxia for the indicated times and analyzed by Western blotting. (C) After cultured in hypoxia for 24 h, cells were reoxygenated (20% O₂) for the indicated times. Protein levels were analyzed by Western blotting. (D) Cells were transfected with increasing amount of the plasmid for HA-scHIF-1 α and analyzed by Western blotting. (E) Cells were transfected with HIF-1 α or HIF-2 α siRNA and then incubated in hypoxia for 24 h. Samples were subjected to Western blotting. (F) Cells were treated for 24 h with hypoxia, DMOG, JNJ-42041935, VH298, or AZD1152. Protein levels were analyzed by Western blotting. (G) Cells were transfected with the indicated siRNAs and subjected to Western blotting.

Fig. 2. Identification of REST as potential target regulated by AURKB and hypoxia. (A) A549 cells were transfected with the control or AURKB siRNA and then incubated in normoxia or hypoxia for 24 h. Each group was designated A1, A2, A3, and A4. Cells were harvested and prepared for DNA microarray analysis. (B) *AURKB* and *VEGFA* mRNA expression levels were analyzed by RT-qPCR. (C) DNA microarray results are shown as a Venn diagram. Considering only the genes that were changed more than 1.5-fold in their expression, '61' in the intersection is the number of genes that were repressed AURKB-dependently by hypoxia. (D) Heat map representing color-coded fold-changes of 61 DEGs identified in DNA microarray. (E) TRANSFAC upstream analysis of DEGs categorized into upregulated (n = 41) and downregulated (n = 20)

sets. Potential upstream transcription factors were ranked by fold change in numbers of predicted transcription factor binding sites within the gene sets compared to the reference gene sets. (F) Proteomic analysis was performed in immunoprecipitated samples derived from cells overexpressing FLAG-AURKB. Transfected cells were incubated in normoxia or hypoxia for 24 h and subjected to immunoprecipitation with anti-FLAG antibody. Genes belonging to the intersection of DNA microarray and proteomic analysis results were identified and presented as a Venn diagram.

Fig. 3. AURKB associates with REST. (A) A549 cell lysates were immunoprecipitated with anti-AURKB antibody, followed by Western blotting. (B) Cell lysates were immunoprecipitated with anti-REST antibody, followed by Western blotting. (C) Cells were transfected with indicated plasmids (WT, wild type; TA, T232A mutant). Lysates were immunoprecipitated with anti-FLAG antibody, followed by Western blotting. (D) Cells were transfected with indicated plasmids and incubated in hypoxia chamber for 24 h. Lysates were subjected to immunoprecipitation and Western blotting.

Fig. 4. Hypoxia and AURKB regulate REST-dependent *MDM2* repression. (A) Fraction of potential REST target genes among DEGs detected in DNA microarray analysis. (B) Top 10 potential REST target genes are ranked by REST-binding score according to the ChIP-Atlas database. (C) A549 cells were transfected with si-REST and subjected to RT-qPCR. (D) Cells were transfected with Myc-REST and analyzed by RT-qPCR. (E) Cells were transfected with si-REST and incubated in hypoxia chamber. Samples were analyzed by RT-qPCR. (F) Cells were transfected with Myc-REST and incubated in hypoxia. Samples were analyzed by RT-qPCR. (G) Cells were cultured under hypoxia and REST binding to the *MDM2* gene was analyzed by ChIP

assay. (H) Cells were treated with si-AURKB and REST binding to the *MDM2* gene was analyzed by ChIP assay. (I) Proposed mechanism for the oxygen-dependent epigenetic regulation of the *MDM2* gene. In the presence of oxygen, AURKB exists in its phosphorylated active form and phosphorylates H3S10 to unwind tight chromatin, which allows the binding partner REST to access DNA. The phosphorylation of AURKB is inhibited in hypoxia through an unknown mechanism, and consequently REST is unable to access the target gene because chromatin is in a condensed state. P, phosphorylated; X, dephosphorylated; ?, unknown.




Fig. 1. Figure 1

Fig. 2




Fig. 2. Figure 2

Fig. 3




Fig. 3. Figure 3

Fig. 4




Fig. 4. Figure 4

**AURKB in concert with REST acts as an oxygen-sensitive
epigenetic regulator in hypoxic induction of MDM2**

Supplementary File

Iljin Kim, Sanga Choi, Seongkyeong Yoo, Mingyu Lee, Jong-Wan Park*

***Corresponding author:** Jong-Wan Park, M.D., Ph.D., Department of Pharmacology,
Seoul National University College of Medicine, 103 Daehak-ro, Seoul 03080, South
Korea. Phone: +82-2-740-8289; Fax: +82-2-745-7996; Email: parkjw@snu.ac.kr

Running title: Oxygen-sensitive epigenetic regulation by AURKB

SUPPLEMENTARY MATERIALS AND METHODS

Cell culture and transfection

Cell lines were acquired from ATCC (Manassas, VA) and cultured in DMEM or RPMI-1640 media supplemented with 10% heat-inactivated FBS and antibiotics (GenDEPOT, Katy, TX). Culture dishes were maintained at 37°C in a humidified condition (5% CO₂). Contamination with mycoplasma was examined on a regular basis. JetPRIME (Polyplus-transfection, Illkirch-Graffenstaden, France) or RNAiMAX (Thermo Fisher Scientific) reagents were used to transfect plasmids and siRNAs.

Reagents and antibodies

DMOG, JNJ-42041935, VH298, and AZD1152-HQPA were purchased from Merck (Darmstadt, Germany). The following antibodies were used: histone H3 (#3638), phospho-histone H3 (#53348), AURKB (#3094), phospho-AURKB (#2914), and Myc-tag (#2278) from Cell Signaling Technology (Danvers, MA); PHD1 (NBP2-59179), PHD2 (NB100-137), and PHD3 (NB100-139) from Novus Biologicals (Centennial, CO); FIH (sc-271780) from Santa Cruz Biotechnology (Dallas, TX); REST from Proteintech (Rosemont, IL); TRIM28 (2521) from ProSci (Poway, CA); MDM2 (AP1254A) from Abcepta (San Diego, CA); HA (11867423001) from Roche Applied Science (Mannheim, Germany); FLAG (F7425) and α -tubulin (T5168) from Merck.

Histone extraction

Cells were lysed with extraction buffer (PBS containing 0.5% Triton X-100 and 2 mM PMSF) and centrifuged at 3000 rpm for 10 min at 4°C. Pellets were resuspended in 0.2N HCl for acid extraction overnight at 4°C by slow rotation. The extract was centrifuged and trichloroacetic acid solution was added to the supernatant containing


histones. Precipitated histone pellets were washed with acetone to remove acid from the solution. Air-dried pellets were dissolved in 50 mM Tris-HCl (pH 7.4) buffer solution.

Bioinformatics analyses


The TRANSFAC database (geneXplain, Wolfenbüttel, Germany) was used to predict potential transcription factors that could regulate differentially expressed genes (DEGs). The fold value was calculated as to how many times the number of sites recognized as the binding sites referring to the same transcription factor was in the input genes compared to the reference gene set. Potential target genes for REST were predicted using an integrated public ChIP-sequencing data platform (<http://chip-atlas.org>).

Statistics


Data were analyzed with the Microsoft Excel and the GraphPad Prism software. All data were considered significant when the p -values were less than 0.05.



Supplementary Fig. S1. (A) Cells were treated with increasing dose of AZD1152 for 24 h and subjected to histone extraction. Cell lysates (p-AURKB, AURKB, and α -tubulin) and histone extraction samples (H3S10p and H3) were analyzed by Western blotting with indicated antibodies. AZD1152, a selective inhibitor of AURKB. (B) Cells were transfected with indicated siRNAs and analyzed by Western blotting.



Supplementary Fig. S2. (A) Cells were transfected with REST siRNA and incubated in hypoxia (1% O₂) for 24 h. Cell lysates were analyzed by Western blotting using indicated antibodies. (B) Cells were transfected with Myc-REST and incubated in hypoxia. Samples were analyzed by Western blotting.



Supplementary Fig. S3. A549 (p53 wild-type) and H1299 (p53 null) cells were transfected with FLAG-AURKB plasmid and analyzed by RT-qPCR. * $p < 0.05$ versus the control group by Student's t-test.

Supplementary Table S1. Differentially expressed genes (upregulated).

Gene	Description	Gene Ontology (GO) annotations
AADACP1	arylacetamide deacetylase pseudogene 1	-
ARL5B	ADP ribosylation factor like GTPase 5B	intracellular protein transport, vesicle-mediated transport, protein localization to Golgi membrane
CAB39	calcium binding protein 39	signal transduction, positive regulation of peptidyl-threonine phosphorylation, response to activity, peptidyl-serine phosphorylation, activation of protein kinase activity, intracellular signal transduction, cellular hypotonic response, positive regulation of protein serine/threonine kinase activity, response to thyroid hormone, negative regulation of potassium ion transmembrane transporter activity, negative regulation of potassium ion transmembrane transport
CCDC90B	coiled coil domain containing 90B	-
CDKL5	cyclin dependent kinase like 5	neuron migration, protein phosphorylation, phosphorylation, positive regulation of GTPase activity, positive regulation of axon extension, protein autophosphorylation, regulation of dendrite development, positive regulation of dendrite morphogenesis, regulation of cell cycle, regulation of postsynapse organization, regulation of cilium assembly
CEP126	centrosomal protein 126	mitotic spindle organization, cell projection organization, cytoplasmic microtubule organization, cilium assembly, non-motile cilium assembly
CIRBP	cold inducible RNA binding protein	response to cold, response to UV, negative regulation of translation, stress granule assembly, positive regulation of translation, positive regulation of mRNA splicing, via spliceosome, mRNA stabilization
CLMP	CXADR like membrane protein	digestive tract development
CSGALNACT2	chondroitin sulfate N acetylgalactosaminyltransferase 2	proteoglycan biosynthetic process, chondroitin sulfate biosynthetic process, chondroitin sulfate proteoglycan biosynthetic process, dermatan sulfate proteoglycan biosynthetic process, polysaccharide chain biosynthetic process, chondroitin sulfate proteoglycan biosynthetic process, polysaccharide chain biosynthetic process
EDA2R	ectodysplasin A2 receptor	epidermis development, ectodermal cell differentiation, cell differentiation, tumor necrosis factor-mediated signaling pathway, positive regulation of I-kappaB kinase/NF-kappaB signaling, positive regulation of JNK cascade, positive regulation of NF-kappaB transcription factor activity, intrinsic apoptotic signaling pathway by p53 class mediator
FAM220A	family with sequence similarity 220 member A	negative regulation of transcription by RNA polymerase II, protein dephosphorylation
FAM86DP	family with sequence similarity 86 member D pseudogene	-
HIPK3	homeodomain interacting protein kinase 3	protein phosphorylation, apoptotic process, mRNA transcription, phosphorylation, peptidyl-serine phosphorylation, peptidyl-threonine phosphorylation, peptidyl-tyrosine phosphorylation, negative regulation of apoptotic process, negative regulation of JUN kinase activity
IL11	interleukin 11	signal transduction, positive regulation of cell population proliferation, B cell differentiation, megakaryocyte differentiation, positive regulation of peptidyl-serine phosphorylation, positive regulation of MAPK cascade, fat cell differentiation, positive regulation of transcription by RNA polymerase II, negative regulation of hormone secretion, positive regulation of peptidyl-tyrosine phosphorylation
KRCC1	lysine rich coiled coil 1	-
LAMP2	lysosomal associated membrane protein 2	protein targeting, autophagy, cellular response to starvation, protein import, negative regulation of protein-containing complex assembly, regulation of protein stability, muscle cell cellular homeostasis, protein stabilization, chaperone-mediated autophagy, protein targeting to lysosome involved in chaperone-mediated autophagy, establishment of protein localization to organelle, autophagosome maturation, lysosomal protein catabolic process
LOC100287704	uncharacterized LOC100287704	-
LOC101929839	uncharacterized LOC101929839	-
LOC105372582	uncharacterized LOC105372582	-
LOC105374160	uncharacterized LOC105374160	-
LOC439994	uncharacterized LOC439994	-
MDM2	MDM2 proto-oncogene	negative regulation of transcription by RNA polymerase II, protein polyubiquitination, blood vessel development, blood vessel remodeling, regulation of heart rate, heart valve development, atrioventricular valve morphogenesis, endocardial cushion morphogenesis, ventricular septum development, atrial septum development, regulation of transcription by RNA polymerase II, ubiquitin-dependent protein catabolic process, apoptotic process, DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest, traversing start control point of mitotic cell cycle, heart development, positive regulation of cell population proliferation, regulation of gene expression, protein ubiquitination, protein sumoylation, protein destabilization, positive regulation of proteasomal ubiquitin-dependent protein catabolic process, protein localization to nucleus,

		transcription factor catabolic process, regulation of protein catabolic process, negative regulation of apoptotic process, proteasome-mediated ubiquitin-dependent protein catabolic process, negative regulation of DNA damage response, signal transduction by p53 class mediator, establishment of protein localization, positive regulation of cell cycle, negative regulation of transcription, DNA-templated, positive regulation of mitotic cell cycle, response to antibiotic, regulation of cellular process, positive regulation of muscle cell differentiation, proteolysis involved in cellular protein catabolic process, regulation of cell cycle, protein autoubiquitination, cardiac septum morphogenesis, protein-containing complex assembly, regulation of biological quality, cellular response to hypoxia, cellular response to gamma radiation, cellular response to actinomycin D, negative regulation of signal transduction by p53 class mediator, negative regulation of intrinsic apoptotic signaling pathway by p53 class mediator, amyloid fibril formation
MIR4673	microRNA 4673	-
MLKL	mixed lineage kinase domain like pseudokinase	MAPK cascade, protein phosphorylation, cell surface receptor signaling pathway, programmed cell death, defense response to virus, protein homotrimerization, necroptotic process, necroptotic signaling pathway, execution phase of necroptosis
RAB8B	RAB8B member RAS oncogene family	vesicle docking involved in exocytosis, protein secretion, protein transport, regulation of exocytosis, antigen processing and presentation, positive regulation of cell projection organization, cellular response to insulin stimulus, protein import into peroxisome membrane, Golgi vesicle fusion to target membrane, positive regulation of corticotropin secretion, protein localization to plasma membrane, cell-substrate junction organization
RANBP9	RAN binding protein 9	cytoskeleton organization, microtubule nucleation, cell surface receptor signaling pathway, protein-containing complex assembly, negative regulation of ERK1 and ERK2 cascade, positive regulation of amyloid precursor protein catabolic process
SCARNA5	small Cajal body specific RNA 5	RNA processing
SLC16A3	solute carrier family 16 member 3	monocarboxylic acid transport, lactate transmembrane transport, plasma membrane lactate transport, transmembrane transport
SNORD116-15	small nucleolar RNA C/D box 116 15	RNA processing
SNORD116-19	small nucleolar RNA C/D box 116 19	RNA processing
SNORD116-2	small nucleolar RNA C/D box 116 2	RNA processing
SNORD116-24	small nucleolar RNA C/D box 116 24	RNA processing
SNORD88A	small nucleolar RNA C/D box 88A	RNA processing
STX4	syntaxin 4	positive regulation of immunoglobulin production, neurotransmitter transport, intracellular protein transport, exocytosis, vesicle fusion, positive regulation of cell population proliferation, vesicle-mediated transport, regulation of exocytosis, positive regulation of cell migration, synaptic vesicle fusion to presynaptic active zone membrane, protein localization to cell surface, cellular response to oxidative stress, SNARE complex assembly, positive regulation of insulin secretion involved in cellular response to glucose stimulus, positive regulation of catalytic activity, positive regulation of eosinophil degranulation, positive regulation of cell adhesion, vesicle docking, organelle fusion, positive regulation of chemotaxis, long-term synaptic potentiation, cellular response to interferon-gamma, regulation of extrinsic apoptotic signaling pathway via death domain receptors, positive regulation of protein localization to plasma membrane, cornified envelope assembly, positive regulation of protein localization to cell surface
TMEM55A	phosphatidylinositol-4,5-Bisphosphate 4-Phosphatase 2	phosphatidylinositol dephosphorylation, negative regulation of phagocytosis
TRNP1	TMF1 regulated nuclear protein 1	cell cycle, nervous system development, cerebellar cortex morphogenesis, regulation of cell population proliferation, regulation of cell cycle, neural precursor cell proliferation
TUBA4B	tubulin alpha 4b	microtubule cytoskeleton organization, mitotic cell cycle, microtubule-based process, biological process
XRN1	5' 3' exoribonuclease 1	nuclear-transcribed mRNA catabolic process, RNA metabolic process, rRNA catabolic process, negative regulation of translation, negative regulation of telomere maintenance via telomerase, response to testosterone, nuclear mRNA surveillance, histone mRNA catabolic process, cellular response to cycloheximide, nucleic acid phosphodiester bond hydrolysis, RNA phosphodiester bond hydrolysis, exonucleolytic, cellular response to puromycin
ZMAT3	zinc finger matrin type 3	apoptotic process, cellular response to DNA damage stimulus, protein transport, regulation of growth
ZNF185	zinc finger protein 185 with LIM domain	-
ZSWIM6	zinc finger SWIM type containing 6	nervous system development, striatal medium spiny neuron differentiation

Supplementary Table S2. Differentially expressed genes (downregulated).

Gene	Description	Gene Ontology (GO) annotations
ACOT4	acyl CoA thioesterase 4	very long-chain fatty acid metabolic process, long-chain fatty acid metabolic process, succinyl-CoA metabolic process, lipid metabolic process, fatty acid metabolic process, fatty acid biosynthetic process, acyl-CoA metabolic process, saturated monocarboxylic acid metabolic process, unsaturated monocarboxylic acid metabolic process, dicarboxylic acid metabolic process, dicarboxylic acid catabolic process, short-chain fatty acid metabolic process
CFHR2	complement factor H related 2	negative regulation of protein binding, cytolysis by host of symbiont cells
DDX11L9	DEAD/H box helicase 11 like 9	-
HCP5	HLA complex P5	-
IGLV1-44	immunoglobulin lambda variable 1 44	adaptive immune response, immune system process, immune response
LOC100240735	uncharacterized LOC100240735	-
LOC101929504	uncharacterized LOC101929504	-
LOC102724580	methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 1 like pseudogene	-
LOC105379829	uncharacterized LOC105379829	-
LOC554207	uncharacterized LOC554207	-
MIR190A	microRNA 190a	gene silencing by miRNA
MIR367	microRNA 367	gene silencing by miRNA
MIR4268	microRNA 4268	-
MIR450A2	microRNA 450a 2	gene silencing by miRNA
OR4N2	olfactory receptor family 4 subfamily N member 2	signal transduction, G protein-coupled receptor signaling pathway, sensory perception of smell, response to stimulus, detection of chemical stimulus involved in sensory perception of smell
SLC35G6	solute carrier family 35 member G6	-
SMIM10	small integral membrane protein 10	-
SNORD114-4	small nucleolar RNA C/D box 114 4	RNA processing
SNRPD2P2	small nuclear ribonucleoprotein D2 pseudogene 2	-
TRGC2	T cell receptor gamma constant 2	-

Supplementary Table S3. Sequences of siRNAs.

siRNA	Sequence (5'-3')
Control	UUGAGCAAUUCACGUUCAUTT
AURKB #1	GGUGAUUCACAGAGACAUAAAGCCA
AURKB #2	GGAGGAGGAUCUACUUGAUUCUAGA
AURKB #3	UACUGUUCUUUAUCUGUUUUUCTA
HIF-1 α	CAAAGUUAAAGCAUCAGGUUCCUUCUU
HIF-2 α	GGGUUACUGACGUGTAAAUGCTGGU
PHD1	CGCACCAAGGCCAUGGUGGCTT
PHD2	AGGAAGAUAAAGCUACUAAUUGAAAA
PHD3	GGAGAAUUAUCACAACCUAAUGACA
FIH	AGGUACAAGCUAUAAGGCAAAGAAT
REST	GUAAAUUCACAGCUAUCAGUUUUUGA

Supplementary Table S4. Sequences of PCR primers.

Gene	Primer	Sequence (5'-3')
AURKB	Primer 1	CATGAGCCGCTCCAATGTC
	Primer 2	TGCTATTCTCCATCACCTTCTGG
VEGFA	Primer 1	AGTGTGTGCCCACTGAGGA
	Primer 2	GGTGAGGTTTGATCCGCATA
ZSWIM6	Primer 1	ACAGTTTGCCAGACATCACTC
	Primer 2	TTCAGTAGCACACGTTACCAG
XRN1	Primer 1	TGTAGATGGTGTGGCTCCT
	Primer 2	AGTTTCTCCCTTCTCTATTGCC
KRCC1	Primer 1	GACTGAACTTTGTTTACAGATACCTT
	Primer 2	GTCCAATTCTCCACTCTCACTC
MDM2	Primer 1	AGAAGGACAAGAACTCTCAGATG
	Primer 2	GTGCATTTCCAATAGTCAGCTAA
MDM2 (ChIP)	Primer 1	ACCCAATTGGCGGAAGCG
	Primer 2	CAGAAGCAGCCAAGCTCGC
CCDC90B	Primer 1	CTTTATCAAATGTCAGCCTGGATAC
	Primer 2	CCATGTCTTTCTGATAGCATCC
ARL5B	Primer 1	GAGTCTCTGCGATCATCCTG
	Primer 2	CAGCCTTCCGTAAATCCTCAT
FAM220A	Primer 1	CTTCCCCTACCTCTACATCGT
	Primer 2	CCTCATGCTTCGTGTTCTTG
CAB39	Primer 1	GGCCTGATGGGATTTAGGAG
	Primer 2	TGCTGGAGATTTGTGAGACTTC
ZNF185	Primer 1	GGCTACAAGATGACCACTGAG
	Primer 2	TCTGACCTCCGTTTCTGTTC
CIRBP	Primer 1	CGGCGGAAGCGTATATAAGG
	Primer 2	TCATCTCTCACCACCTCTCC
GAPDH	Primer 1	ACATCGCTCAGACACCATG
	Primer 2	TGTAGTTGAGGTCAATGAAGGG